Event driven look at PACS Group stock

PACS Group (PACS) just paired a reaffirmed 2026 revenue outlook of US$5.65 billion to US$5.75 billion with first quarter results that show higher revenue and net income versus a year ago.

The company also approved a US$250 million share repurchase program and highlighted ongoing acquisition discussions for 2026, giving investors several fresh data points on earnings power and capital allocation priorities.

Despite the reaffirmed 2026 revenue outlook, strong first quarter results, and the new buyback plan, PACS Group’s recent share price performance is mixed. The stock is at US$37.75, with a 1-month share price return of 6.55% but a year-to-date share price return that is down 4.45%, while the 1-year total shareholder return is about 3x.

If you are weighing PACS Group against other healthcare-related ideas, this can be a good moment to broaden your watchlist with a curated set of 34 healthcare AI stocks

With PACS Group trading at US$37.75, a stated intrinsic discount of about 37% and a fresh US$250 million buyback in place, is the stock still underappreciated, or is the market already pricing in future growth?

Most Popular Narrative: 7.9% Overvalued

The most followed narrative pegs PACS Group’s fair value around $35, a touch below the last close at $37.75, and builds that gap on a detailed earnings roadmap.

Systematic improvement of newly acquired and turnaround facilities from low single digit margins toward the high single digit and low double digit margin profile of mature sites should unlock embedded profitability, lifting consolidated net margins and EBITDA over time.

Read the complete narrative. Read the complete narrative.

Want to see what is behind that margin lift story? The narrative leans heavily on rising occupancy, richer case mix, and a step change in profitability over the next few years. The exact earnings path and valuation math sit in the full set of forecasts and assumptions.

Result: Fair Value of $35 (OVERVALUED)

However, the recent audit investigation and the heavy reliance on Medicaid structures could easily shift sentiment if compliance or reimbursement trends move against expectations.

Another View: Cash Flows Point to a Different Story

The analyst narrative sits around a fair value of $35 and tags PACS Group as about 7.9% overvalued, but the SWS DCF model paints a different picture. On that cash flow view, the stock at $37.75 is trading below an estimated value of $60.42, which frames it as undervalued instead. That kind of gap raises a simple question: which set of assumptions do you trust more, the earnings roadmap or the cash flow math?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out PACS Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment running both cautious and optimistic, it makes sense to move quickly and test the numbers yourself against the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop with just one stock. Use powerful screeners to uncover fresh ideas that fit your style before the next set of opportunities moves out of reach.

• Target reliable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair financial strength with room for future decisions.
• Spot potential mispricings early by scanning the 48 high quality undervalued stocks and compare current prices with underlying business quality.
• Seek standout opportunities off the beaten path by checking the screener containing 21 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.